PDF-Guidance for Clinical Investigators Sponsors and Investigational New D PDF document

NOTE A stay is in effect for partsof subsection VID of this guidance dditional information about this staycan be found inthe Notice of Stay that published in the

Upload by jade
Published on 2021-10-07

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/897449" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "Guidance for Clinical Investigators Spon..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Guidance for Clinical Investigators Sponsors and Investigational New D: Transcript

PDF-Guidance for Clinical Investigators Sponsors and Investigational New D PDF document

Presentation Embed Code

Download Presentation

Guidance for Clinical Investigators Sponsors and Investigational New D: Transcript

Related Contents

Contains Nonbinding Recommendations Information Sheet Guidance For IRBs Clinical Investigators

Informed Consent Information Sheet Guidance for IRBs Clinical Investigators and Sponsors

Guidance for IRBs Clinical Investigators and Sponsors Considerations When Transf

Guidance on legislation Clinical investigations of medical devices guidance for investigators

Pamela Harris, M.D. Percy Ivy, M.D

Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs

Information Sheet Guidance for Sponsors Clinical Inves

Quality Issues for Clinical Trial Materials

Guidance for Sponsors, Institutional Review Boards, Clinical Investiga

Contract Research organizations

Stephen A. Bean, PharmD

1 King & Spalding May 22, 2014

Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in

Guidance for Industry CGMP for Phase Investigational Drugs U